Announcing a Single Shared REMS for all TIRF Medicines

Starting on March 12, 2012, one Risk Evaluation and Mitigation
Strategy (REMS) will replace the individual REMS for Transmucosal
Immediate-Release Fentanyl (TIRF) medicines.

The goals of this program are to mitigate the risks of misuse, abuse, addiction,
overdose, and serious complications due to medication errors.

Click the button to the right for additional information.